Associate Scientific Director, Biomarkers and Diagnostics, Colorectal Cancer Interception
Janssen R&D US
Why I'm a JPAL
I am interested in becoming a JPAL in order to build relationships with up-and-coming companies and stay on top of new technologies that can advance the Colorectal Cancer Interception group's objectives.
I earned my PhD in Microbiology and Immunology from the University of North Carolina at Chapel Hill, with a focus on studying the innate immune response to antibody-enhanced dengue virus infection in primary human monocytes. In industry, I have been in both discovery and development organizations. Originally starting with GlaxoSmithKline in 2015, I joined the Dermatology group discovering biomarkers of skin diseases and performing early target discovery and validation activities, including for non-melanoma skin cancers. In 2018, I transitioned to Oncology R&D where I served as a clinical biomarker lead on the clinical team of multiple immuno-oncology assets. In April 2020, I joined the Colorectal Cancer (CRC) Interception group in Janssen Oncology R&D, where I lead many of the risk identification efforts to understand who is at risk of future development of disease and could be a candidate for therapeutic intervention to prevent CRC development.